The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway

The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway

Oncogenic mutations of isocitrate dehydrogenases 1 and 2 result in the production of the oncometabolite R-2-hydroxyglutarate. Here the authors show that the oncometabolite promotes mTOR activation in a PTEN/PI3K-independent manner by regulating DEPTOR stability via inhibition of KDM4A activity.

Bibliographic Details
Main Authors: Mélissa Carbonneau, Laurence M. Gagné, Marie-Eve Lalonde, Marie-Anne Germain, Alena Motorina, Marie-Christine Guiot, Blandine Secco, Emma E. Vincent, Anthony Tumber, Laura Hulea, Jonathan Bergeman, Udo Oppermann, Russell G. Jones, Mathieu Laplante, Ivan Topisirovic, Kevin Petrecca, Marc-Étienne Huot, Frédérick A. Mallette
Format: Article
Language:English
Published: Nature Publishing Group 2016-09-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/ncomms12700

Internet

https://doi.org/10.1038/ncomms12700

Similar Items